SCHEMBL1480802

SCHEMBL1480802

CCOc1ccc(-c2ccc(/C=C/c3nc(-c4ccc(Cl)cc4Cl)cn3CC)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM4E B2RXH2 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
MAOB P27338 1/20 0.37
RELA Q04206 1/20 0.37
ESR1 P03372 2/20 0.37
AHR P35869 1/20 0.37
LMNA P02545 1/20 0.36
ATP4A P20648 1/20 0.35
ATP4B P51164 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35
TUBB4B P68371 1/20 0.35
TUBB3 Q13509 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480804 1.00 MAPT (0.41) MAPTTP53SMN1; SMN2KDM4ETDP1
SCHEMBL1480187 0.91 DPP4 (0.43) MAPTRELAAHRLMNADPP4
SCHEMBL1480190 0.91 DPP4 (0.43) MAPTRELAAHRLMNADPP4
SCHEMBL1482040 0.89 MAOB (0.40) MAPTTP53SMN1; SMN2KDM4ETDP1
SCHEMBL1482038 0.89 MAOB (0.40) MAPTTP53SMN1; SMN2KDM4ETDP1
SCHEMBL1481290 0.89 MAP4K4 (0.41) TDP1MEN1KMT2ACNR1KCNA3
SCHEMBL1481291 0.89 MAP4K4 (0.41) TDP1MEN1KMT2ACNR1KCNA3
SCHEMBL6532596 0.88 KMT2A (0.36) MAPTTP53SMN1; SMN2KDM4ETDP1
SCHEMBL6532595 0.88 KMT2A (0.36) MAPTTP53SMN1; SMN2KDM4ETDP1
SCHEMBL1480782 0.88 RELA (0.42) MAPTSMN1; SMN2KDM4ERELAAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885TP53 1088/4885SMN1; SMN2 4575/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885TP53 1088/4885SMN1; SMN2 4575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.